A rationally designed class of mTORC1 inhibitors combines the selectivity of rapamycin with the potency of mTOR kinase inhibitors.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Saxton, R. A. & Sabatini, D. M. Cell 168, 960–976 (2017).
Benjamin, D., Colombi, M., Moroni, C. & Hall, M. N. Nat. Rev. Drug Discov. 10, 868–880 (2011).
Lee, B. J. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-021-00813-7 (2021).
Choo, A.Y., Yoon, S.O., Kim, S.G., Roux, P.P. & Blenis, J. Proc. Natl. Acad. Sci. USA 105, 17414–17419 (2008).
Feldman, M. E. et al. PLoS Biol. 7, e38 (2009).
Thoreen, C. C. et al. J. Biol. Chem. 284, 8023–8032 (2009).
Dowling, R. J. et al. Science 328, 1172–1176 (2010).
Rodrik-Outmezguine, V. S. et al. Nature 534, 272–276 (2016).
Sarbassov, D. D. et al. Mol. Cell 22, 159–168 (2006).
Kennedy, B. K. & Lamming, D. W. Cell Metab. 23, 990–1003 (2016).
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Thoreen, C.C. Split-personality inhibitors. Nat Chem Biol 17, 1012–1013 (2021). https://doi.org/10.1038/s41589-021-00820-8